NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)Sairah Ahmed, Joseph P. McGuirk, John F. DiPersio et al.|Transplantation and Cellular Therapy|2025Cited by 3
CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Scott S. Tykodi et al.|Unknown|2023Cited by 0
Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Michael E. Hurwitz et al.|Unknown|2023Cited by 0
Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Unknown|2023Cited by 0
Supplementary Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Michael E. Hurwitz et al.|Unknown|2023Cited by 0